Medscape is available in 5 Language Editions – Choose your Edition here.


Kawasaki Disease

  • Author: Noah S Scheinfeld, JD, MD, FAAD; Chief Editor: Russell W Steele, MD  more...
Updated: Sep 13, 2015

Practice Essentials

Kawasaki disease (KD) (see the image below) is an acute febrile vasculitic syndrome of early childhood that, although it has a good prognosis with treatment, can lead to death from coronary artery aneurysm (CAA) in a very small percentage of patients.

Pediatrics, Kawasaki disease. Note the appearance Pediatrics, Kawasaki disease. Note the appearance of the hand and lips. Photo courtesy of Sam Richardson, MD.

See Kawasaki Disease: Do You Know the Signs?, a Critical Images slideshow, to help identify the specific criteria for diagnosis.

Signs and symptoms

Kawasaki disease produces prolonged fever (often abrupt in onset and preceded by several days of nonspecific symptoms) along with a constellation of clinical features that includes the following:

  • Irritability
  • Nonexudative bilateral conjunctivitis (90%)
  • Anterior uveitis (70%)
  • Perianal erythema (70%)
  • Sterile pyuria
  • Erythema and edema on the hands and feet; the latter impedes ambulation
  • Strawberry tongue and lip fissures
  • Hepatic, renal, and GI dysfunction
  • Myocarditis and pericarditis
  • Lymphadenopathy (75%); generally, a single, enlarged, nonsuppurative cervical node measuring approximately 1.5 cm

See Clinical Presentation for more detail.


Diagnostic criteria established by the American Heart Association (AHA) are fever lasting longer than 5 days and 4 of the 5 following main clinical features:[1, 2, 3, 4, 5]

  • Changes in the peripheral extremities: Initial reddening or edema of the palms and soles, followed by membranous desquamation of the finger and toe tips or transverse grooves across the fingernails and toenails (Beau lines)
  • Polymorphous rash (not vesicular): Usually generalized but may be limited to the groin or lower extremities
  • Oropharyngeal changes: Erythema, fissuring, and crusting of the lips; strawberry tongue; diffuse mucosal injection of the oropharynx
  • Bilateral, nonexudative, painless bulbar conjunctival injection
  • Acute nonpurulent cervical lymphadenopathy with lymph node diameter greater than 1.5 cm, usually unilateral

The acronym FEBRILE is used to remember the criteria as follows:

  • Fever
  • Enanthem
  • Bulbar conjunctivitis
  • Rash
  • Internal organ involvement (not part of the criteria)
  • Lymphadenopathy
  • Extremity changes

If a patient presents with 4 or more of the principal criteria, AHA guidelines suggest that Kawasaki disease can be diagnosed on day 4 of the fever.

Echocardiography is the study of choice to evaluate for coronary artery aneurysms. Serial echocardiograms should be obtained as follows:

  • At the time of Kawasaki disease diagnosis
  • At 2 weeks
  • At 6-8 weeks after the onset of the illness

No specific laboratory test is used to diagnose Kawasaki disease. Initially, almost all patients have elevated levels of the following acute-phase reactants:

  • Erythrocyte sedimentation rate (ESR)
  • C-reactive protein (CRP)
  • Alpha1-antitrypsin

More recently, 2 urine proteins, meprin A and filamin C , have been shown to be diagnostically superior to ESR or CRP and hold promise as biomarkers of Kawasaki disease.[6, 7]

See Workup for more detail.


The principal goal of treatment is to prevent coronary artery disease and to relieve symptoms. Full doses of intravenous immunoglobulin (IVIG) are the mainstay of treatment.[5, 8, 9] Aspirin (high-dose for a variable period, followed by low-dose) has traditionally been standard, as well.

Other medications include the following:

  • Corticosteroids: Typically in patients unresponsive to standard therapies
  • Methotrexate or cyclophosphamide: In IVIG-resistant cases
  • Infliximab: In refractory cases with coronary aneurysms [10]
  • Antiplatelet medications (eg, clopidogrel, dipyridamole): In patients at increased risk for thrombus with significant coronary involvement
  • Anticoagulants (eg, warfarin, low-molecular-weight heparin): In patients with large aneurysms in whom the risk of thrombus is high
  • A new treatment used in Japan for patients who are resistant to IVIG is ulinastatin (UTI), a neutrophil elastase inhibitor used to treat patients with circulatory shock or pancreatitis. A number of studies have shown ulinastatin efficacy for KD. [11]


Clinical guidelines include the following:

See Treatment and Medication for more detail.



Kawasaki disease (KD), or Kawasaki syndrome, is an acute febrile vasculitic syndrome of early childhood. The disorder has also been called mucocutaneous lymph node syndrome and infantile periarteritis nodosa. Kawasaki disease was first described in 1967 by Dr Tomisaku Kawasaki, who reported 50 cases of a distinctive illness in children seen at the Tokyo Red Cross Medical Center in Japan.[1] These children presented with fever, rash, conjunctival injection, cervical lymphadenitis, inflammation of the lips and oral cavity, and erythema and edema of the hands and feet. The photographs below depict various manifestations of Kawasaki disease.

Patchy generalized macular erythema, which is also Patchy generalized macular erythema, which is also typical of some viral exanthems.
Peeling and erythema of the fingertips. Peeling and erythema of the fingertips.
Strawberry tongue. Strawberry tongue.

The illness was initially thought to be benign and self-limited. However, subsequent reports indicated that nearly 2% of patients with Kawasaki disease later died from the illness. Fatalities occurred among children younger than 2 years. These children died while they were improving or after they had seemingly recovered. Postmortem examinations revealed complete thrombotic occlusion of coronary artery aneurysms (CAAs), with myocardial infarction (MI) as the immediate cause of death.

In 1976, Melish et al first reported Kawasaki disease in the United States, in a group of 12 children from Honolulu examined from 1971-1973.[12] Kawasaki disease is now recognized worldwide, although the greatest number of cases has been in Japan. It is the leading cause of acquired heart disease in children in the developed world and may be a risk factor for adult ischemic heart disease. In the United States, Kawasaki disease has surpassed acute rheumatic fever as the leading cause of acquired heart disease in children younger than 5 years.[13]

Echocardiographic studies have shown that 20-25% of untreated children with Kawasaki disease develop cardiovascular sequelae ranging from asymptomatic coronary artery ectasis or aneurysm formation to giant CAAs with thrombosis, MI, and sudden death. The mortality rate is 0.1-2%. Early administration of intravenous immunoglobulin (IVIG) reduces the risk of developing cardiac involvement to 5%. Although inflammatory infiltrates have been shown in the pancreas, kidney, and biliary tract, no significant sequelae persist in those tissues.

Because no specific test can be performed for Kawasaki disease and no clinical feature is pathognomonic, the diagnosis of Kawasaki disease is based on the presence of a constellation of clinical findings. Classic cases demonstrate prolonged fever along with at least 4 of 5 major clinical features. (See Presentation.)

In so-called incomplete cases, febrile patients appear to have Kawasaki disease but do not meet diagnostic criteria and have no other identified cause of their illness. Laboratory testing supports the diagnosis in these cases (see Workup).

Although most patients recover with little to no physical activity limitations, a delay in diagnosis results in a greater likelihood of coronary lesions and complications thereof; therefore, a provider must be aware of the classic and atypical presentation of this disease to ensure an optimal patient outcome. Therapy should be started within 10 days, and ideally within 7 days, of fever onset.[14]

Coronary artery aneurysms manifest in 25% of untreated KD can remain clinically silent for years and subsequently thrombose causing myocardial infarction. KD currently is the most common etiology of acquired heart disease occurring in children the United States, in Asia, and Western Europe. Cardiologists must be aware that coronary artery aneurysms that occur in young adults can be the result of missed KD in childhood.[15]

IVIG and aspirin have constituted the mainstays of therapy for Kawasaki disease. However, the usefulness of aspirin has been called into question. Other agents, such as corticosteroids and infliximab, have been used in patients with disease refractory to IVIG.[16] (See Treatment.)



Despite the prominent mucocutaneous clinical findings that define the illness, Kawasaki disease is best regarded as a generalized vasculitis that involves small- to medium-sized arteries. Although the vascular inflammation is most pronounced in the coronary vessels, vasculitis can also occur in veins, capillaries, small arterioles, and larger arteries.

In the earliest stages of the disease, the endothelial cells and the vascular media become edematous, but the internal elastic lamina remains intact. Then, approximately 7-9 days after the onset of fever, an influx of neutrophils occurs, which is quickly followed by a proliferation of CD8+ (cytotoxic) lymphocytes and immunoglobulin A–producing plasma cells.

The inflammatory cells secrete various cytokines (ie, tumor necrosis factor, vascular endothelial growth factor, monocyte chemotactic and activating factor), interleukins (ILs; ie, IL-1, IL-4, IL-6), and matrix metalloproteinases (MMPs; ie, primarily MMP3 and MMP9) that target the endothelial cells and result in a cascade of events that eventuates in fragmentation of the internal elastic lamina and vascular damage.[17]

In severely affected vessels, the media develops inflammation with necrosis of smooth muscle cells. The internal and external elastic laminae can split, leading to aneurysms.

Over the next few weeks to months, the active inflammatory cells are replaced by fibroblasts and monocytes, and fibrous connective tissue begins to form within the vessel wall. The intima proliferates and thickens. The vessel wall eventually becomes narrowed or occluded owing to stenosis or a thrombus.[18, 19, 20, 21, 22] Cardiovascular death may occur from a myocardial infarction secondary to thrombosis of a coronary aneurysm or from rupture of a large coronary aneurysm.

Most of the pathology of the disease is induced by a medium vessel arterial vasculitis. Initially, neutrophils are present in great numbers, but the infiltrate rapidly switches to mononuclear cells, T lymphocytes, and immunoglobulin A (IgA)–producing plasma cells. Inflammation involves all 3 layers of vessels. Eosinophils are preferentially accumulated in microvessels.

The period during of the greatest vascular damage is when a concomitant progressive increase in the serum platelet count occurs, and this is the point of the illness when the risk of death is most significant.

Endothelin-1 (ET-1), pentraxin 3 (PTX3), N-terminal pro-brain natriuretic peptide, and brain natriuretic peptide (BNP) are made and secreted from vascular and/or myocardial tissue. They are also useful in the prediction of coronary artery lesions formation and IVIG non-responsiveness and in KD’s acute phase. Some biomarkers can help evaluate atherosclerosis and chronic coronary arteritis and KD’s convalescent phase.[23]



The etiology of Kawasaki disease remains unknown. At present, most of the epidemiologic and immunologic evidence indicates that the causative agent is probably infectious. However, autoimmune reactions and genetic predisposition have been suggested as possible etiologic factors. By 2014, 6 genetic loci have been linked to KD through genome-wide studies but the etiology of KD complex and these genetic factors still need to be fully applied to diagnosis and treatment.[24]

In 2007, the US Food and Drug Administration (FDA) required the makers of RotaTeq rotavirus vaccine to report in the package insert that 9 cases of Kawasaki disease had occurred in children who had received the vaccine. However, most believe that there is no connection between the vaccine and the disease.[25] One case report in the literature documents a 35-day-old infant who developed Kawasaki disease after his second hepatitis B vaccination.[26]


Features of Kawasaki disease that are consistent with an infectious etiology include the occurrence of epidemics primarily in late winter and spring with 3-year intervals and the wavelike geographic spread of those epidemics; the self-limited nature of the disease; and the characteristic fever, adenopathy, and eye signs. Kawasaki disease is unusual in infants younger than 4 months, suggesting that maternal antibodies may provide passive immunity. Epidemiologic data suggest, however, that person-to-person transmission of the disease is unlikely.

Some authors have proposed a controversial association of Kawasaki disease with recent carpet shampooing, flooding, the use of a humidifier in the room of a child with an antecedent respiratory illness,[27] and locations near bodies of water.[28] These data have led to a waterborne vector hypothesis.

The overall clinical presentation of patients with Kawasaki disease is similar to that of patients with a viral or superantigenic disease. However, investigations have shown that the immune response in Kawasaki disease is oligoclonal, which is seen as a response to a conventional antigen, rather than polyclonal, as would be found in a superantigen-driven response.[29, 30]

Over the years, multiple infectious agents have been implicated; however, to date, no single microbial agent has surfaced as the prevailing cause.[31, 32] Suspected pathogens and infections have included the following:

  • Parvovirus B19
  • Meningococcal septicemia
  • Bacterial toxin–mediated superantigens
  • Mycoplasma pneumoniae
  • Klebsiella pneumoniae bacteremia
  • Adenovirus
  • Cytomegalovirus [33]
  • Parainfluenza type 3 virus
  • Rotavirus infection
  • Measles
  • Epstein-Barr virus
  • Human lymphotropic virus infection
  • Mite-associated bacteria
  • Tick-borne diseases
  • Rickettsia species
  • Propionibacterium acnes

Using light and electron microscopy, researchers have identified cytoplasmic inclusion bodies containing RNA in 85% of acute- and late-stage Kawasaki disease fatalities and 25% of adult controls. Based on this finding, it is hypothesized that the Kawasaki disease infective agent is most likely a ubiquitous RNA virus that results in asymptomatic infection in most individuals but leads to Kawasaki disease in a subset of genetically predisposed individuals.

It is postulated that the virus enters via a respiratory route, activating both the innate and adaptive immune system and resulting in B lymphocytes switching to immunoglobulin A (IgA) lymphocytes. The identity of this virus or group of closely related viruses is still under investigation.[17]

Genetic factors

A genetic predilection to Kawasaki disease has long been suspected.[34, 35] Siblings of affected children have a 10-20 times higher probability of developing Kawasaki disease than the general population, and children in Japan whose parents had Kawasaki disease seem to have a more severe form of the disease and to be more susceptible to recurrence.[36] This risk of 2 family members having Kawasaki disease is greatest in twins, for whom the rate is approximately 13%.[37]

In 1978, Kato et al discovered that patients with Kawasaki disease are more likely to express HLA-Bw22J2, which is a major histocompatibility complex antigen seen predominantly in Japanese populations, thereby further implicating a genetic influence to the increased susceptibility to Kawasaki disease in Japanese patients.[38, 39] A genome-wide linkage analysis of affected sibling pairs was performed in Japan, and a multipoint linkage analysis identified evidence of linkage on chromosome 12q24.[40]

Dergun et al, Newburger et al, and Burns et al described families with multiple members affected with Kawasaki disease.[41, 13, 42] In these families, Kawasaki disease occurred in 2 generations or in multiple siblings. No clear pattern of inheritance could be deduced from these pedigrees. Therefore, multiple polymorphic alleles likely influence Kawasaki disease susceptibility.

A functional polymorphism of the inositol 1,4,5-triphosphate 3-kinase C (ITPKC) gene on band 19q13.2 has been found to be significantly associated with an increased susceptibility to developing Kawasaki disease. In addition, this polymorphism was associated with an increased risk of coronary artery lesions in both Japanese and US children.[43]

In a Dutch cohort, Breunis et al observed an association of Kawasaki disease with common genetic variants in the chemokine receptor gene-cluster CCR3-CCR2-CCR5.[44] The association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki disease, coronary artery lesions, and responses to intravenous immunoglobulin have been reported in Japanese children and in other children.[45]

A genomic study by Taniuchi et al found that genetic factors may influence the development of coronary artery lesions in Kawasaki disease.[46] In this study, genomic DNA was extracted from whole blood collected from 56 patients with Kawasaki disease who received gamma globulin treatment, and the genotypes for Fcg RIIIb-NA(1,2), Fcg RIIa-H/R131, and Fcg RIIIa-F/V158 were determined.

About 23% of patients with the HH allele for the Fcg RIIa polymorphism developed coronary artery lesions, compared with 60% with the HR and RR alleles. HR and RR alleles may be a predictor of the progression of coronary lesions in Kawasaki disease before the start of gamma-globulin therapy. Furthermore, a polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease.



United States statistics

Epidemics of Kawasaki disease primarily occur in the late winter and spring, at 2- to 3-year intervals. Approximately 3000 children with Kawasaki disease are hospitalized annually in the United States. The approximate annual race-specific incidence per 100,000 children younger than 5 years is 32.5 cases for Americans of Asian and Pacific Island descent, 16.9 cases for non-Hispanic African Americans, 11.1 cases for Hispanics, and 9.1 cases for whites.[4]

A 2010 article retrospectively examined all hospitalizations of children younger than 18 years who have Kawasaki disease and found that the rate of hospitalization in the United Sates from 1997-2007 remained relatively stable, except for a slight increase in 2005. The hospitalization rate for children younger than 5 years (mean age, 1.6 years) was 20.8 cases per 100,000 children in 2006 and demonstrated a slight male predilection.[47]

International statistics

Outside the United States, the disease is most frequently observed in Japan, Taiwan, and Korea. The prevalence of Kawasaki disease increased from 1967 to the mid-1980s and has leveled out at 5000-6000 cases per year. The highest incidence of Kawasaki disease has been reported in Japan, where the frequency of the disease is 10 to 20 times higher than in Western countries.[43]

A large, international-based registry of Kawasaki disease in children of non East-Asian descent reported that, relative to children with other febrile illnesses, children with incomplete or atypical Kawasaki disease had statistically significant increases in the occurrence of conjunctivitis, mucosal changes, extremity alteration, and perineal desquamation.[48] These children also expressed elevated C-reactive protein and platelet counts.[48]

Approximately 5000-6000 cases are reported each year in Japan. The incidence in 2000 was 134.2 cases per 100,000 children younger than 5 years. Epidemics occurred in Japan during the years 1979, 1982, and 1985. No epidemics have occurred since that time.

Marked spatial and temporal patterns were noted in both the seasonality and deviations from the average number of Kawasaki disease cases in Japan. Seasonality was bimodal, with peaks in January and June and/or July and a nadir in October. This pattern was consistent throughout Japan during the entire 14-year period. Very high or low numbers of cases were reported in certain years, but the overall variability was consistent throughout the entire country. Temporal clustering of Kawasaki disease cases was detected with nationwide outbreaks.[49]

A review by Yanagawa et al of the epidemiology of Kawasaki disease in Japan from 1999-2002 found that 18,604 boys and 13,662 girls with Kawasaki disease were reported. The average annual incidence was 137.7 cases per 100,000 children younger than 5 years.[50] Most cases occurred in January.

Park et al noted the average annual rate of incidence of Kawasaki disease in South Korea was 105 cases per 100,000 in children younger than 5 years, which was the second highest reported rate in the world.[51] On average, the approximate annual incidence of Kawasaki disease in various Asian populations per 100,000 children younger than 5 years is 54.9 cases for Taiwan, 25.4 cases for Hong Kong, 16.8-36.8 cases for Shanghai, and 18.2-30.6 cases for Beijing.

The annual incidence reported in white populations outside the United States is similar to that reported in the US population, with 11.3-14.7 cases per 100,000 children younger than 5 years in Canada and 3.6 cases per 100,000 children younger than 5 years in Australia.[52, 53] From 1999-2000, the incidence in the United Kingdom was 8.1 cases per 100,000 children.[54]

Ontario has the highest rate of Kawasaki disease outside of Asia, with a yearly incidence of 26.2 cases per 100,000 population younger than 5 years. The incidence significantly increased from 1995 to 2006, with more patients diagnosed with incomplete Kawasaki disease. A reduction in coronary abnormalities was also seen during this period and was attributed to better recognition and treatment of the disease.[55]

Racial and sexual differences in incidence

Although Kawasaki disease has been reported in children of all ethnic origins, it occurs most commonly in Asian children, especially those of Japanese descent. Rates are intermediate among blacks, Polynesians, and Filipinos and are lowest among whites. Studies show that the incidence rate and number of patients with KD have increased since the mid-1990s in Japan.[56]

Kawasaki disease is slightly more common in males than in females. The male-to-female ratio ranges from 1.3-1.83:1 depending on the country from which the statistics are reported.[47] Arthritis appears to be more common in girls than in boys. Death and serious complications are more common in boys than in girls.

Age-related differences in incidence

Approximately 85-90% of Kawasaki disease cases occur in children younger than 5 years[33] ; 90-95% of cases occur in children younger than 10 years. In the United States, the incidence peaks in children aged 18-24 months. In Japan, the incidence peaks in children aged 6-12 months. The earliest reported case in Japan occurred in a 20-day-old newborn.

Kawasaki disease has rarely been reported in adolescents and adults, most of whom are between ages 18 and 30 years.[55] Fewer than 60 adult patients have been described in the literature for various geographic locations, including 25 in Europe, 23 in North America, 5 in Asia, 2 in South America, and 2 in Africa.[2]

Kawasaki-like syndromes have been reported in adults infected with human immunodeficiency virus (HIV). However, it is unclear whether this is a variant of Kawasaki disease or an unrelated entity in the immunocompromised population.[57]

Pannaraj et al noted that Kawasaki disease may occur at the extremes of the typical age range (ie, infants younger than 6 months or children older than 5 years).[58] Manlhiot et al suggest that children younger than 6 months and those older than 9 years, are more likely to have a suboptimal outcome.[59]

The majority of "incomplete" cases (see below) occur in very young children.[60] Infants aged 6 months or younger may have maternal antibody protection, but incomplete cases—and some of the poorest outcomes—have been reported in that age group.[60]



With prompt treatment, the prognosis is good. Data are limited, but in the United States, death occurs in approximately 1% of affected children. In children younger than 1 year, the mortality rate may exceed 4%. In patients aged 1 year or older, the death rate is probably less than 1%. The average mortality rate in Japan is 0.1-0.3%. The peak mortality occurs 15-45 days after the onset of fever. To date, no deaths have been reported in adult cases of Kawasaki disease.[2]

Kawasaki disease has surpassed rheumatic heart disease as the leading cause of acquired heart disease in the US in children under the age of 5 years. Cardiovascular complications include the following:

  • Clinically significant heart failure or myocardial dysfunction (unlikely to occur once fever is resolved)
  • Diffuse coronary artery ectasia and aneurysm formation, giant aneurysm (internal luminal diameter ≥8 mm)
  • Myocardial infarction (MI)
  • Myocarditis (common but rarely causes chronic heart failure)
  • Valvulitis, usually mitral (only occurs in 1% of patients and rarely requires valve replacement)
  • Pericarditis with small pericardial effusions (occurs in 25% of patients with acute illness)
  • Systemic arterial aneurysms
  • More severe Kawasaki disease, as indicated by sterile pyuria (can be marked by elevated levels of C-reactive protein, erythrocyte sedimentation rate, serum alanine aminotransferase) [61]
  • Rupture of coronary artery aneurysms with hemopericardium

Approximately 20-25% of untreated patients develop cardiac problems, including coronary artery aneurysms (CAAs). Aneurysms develop in less than 5-10% of patients treated with intravenous gamma globulin before the 10th day of illness.[4]

Patients who do not develop CAAs recover fully. In those who do develop CAAs, the severity of aneurysms determines the prognosis. More than half of all aneurysms resolve by the 2-year mark. Endovascular ultrasonography has shown that, even when aneurysms resolve, marked intimal thickening is present in some. Vessel flow may be abnormal. These patients may have an increased risk of premature coronary atherosclerotic disease.[62]

Coronary artery bypass grafting (CABG) has been required in some children with severe perfusion deficits. Follow-up of children and adolescents 20-25 years after CABG has shown a 95% survival rate, though some patients have required repeat CABG or percutaneous coronary intervention.[63] Transplant has been performed in some children who had large aneurysms in vessels not amenable to bypass.

Arthritis persists in some children. Kawasaki disease appears to be a rare cause of adult cardiac dysfunction.

Risk factors for aneurysm include the following:

  • Fever for more than 16 days
  • Recurrence of fever after an afebrile period of at least 48 hours
  • Male sex
  • Cardiomegaly
  • Age younger than 1 year

Laboratory values at presentation that may predict a greater likelihood of aneurysm development include the following:

  • Hematocrit < 35%
  • Thrombocytopenia (< 350,000/μL)
  • Elevated C-reactive protein level
  • Albumin < 3.5 g/dL
  • White blood cell count >12,000/μL

Incomplete Kawasaki disease may also be an independent predictor of CAA development.[64] The most important predictor is total duration of fever longer than 8 days.[60] Wilder's group reported that delayed diagnosis contributes to the development of these aneurysms.[65]

Studies have shown that even in children who do not form aneurysms, up to 50% show a decrease in ventricular function and/or mild valvular regurgitation on echocardiograms. The greatest risk of cardiac damage occurs in children younger than 1 year and in older children, which may be related to an atypical presentation often seen in this age group that leads to a delay in treatment.

Recurrence is unusual: the recurrence rate in Japan is 3% and approximately 1% in North America. Most relapses occur within 2 years from the initial episode. The highest incidence is in younger children and those who had cardiac sequelae from the initial episode. The incidence also appears to be slightly increased in cases within families, with approximately 2.1% of siblings affected within 10 days to 1 year from the first sibling's illness.


Patient Education

The fact that most cases resolve must be communicated to the patient and family, as well as the fact that Kawasaki disease can be fatal. Also educate patients about the possibility of recurrence. The recurrence rate is 4% in Japan but is less than 1% in North America.

Emphasize the need for continued care if cardiac problems are present, because Kawasaki disease is a potentially fatal illness. Advise the patient's family that aspirin therapy must be continued until discontinued by the physician.

Parents and other caregivers must understand the need for close pediatric and cardiology follow-up until the disease has fully resolved. Physicians should also make affected families aware of the potential increased risk of Kawasaki disease among family members.

Contributor Information and Disclosures

Noah S Scheinfeld, JD, MD, FAAD Assistant Clinical Professor, Department of Dermatology, Weil Cornell Medical College; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Assistant Attending Dermatologist, New York Presbyterian Hospital; Assistant Attending Dermatologist, Lenox Hill Hospital, North Shore-LIJ Health System; Private Practice

Noah S Scheinfeld, JD, MD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Abbvie<br/>Received income in an amount equal to or greater than $250 from: Optigenex<br/>Received salary from Optigenex for employment.


Steven J Parrillo, DO, FACOEP, FACEP Clinical Adjunct Professor, Medical Director and Faculty, Disaster Medicine and Management Masters Program, Philadelphia University College of Health Sciences; Associate Professor, Clinical and Educational Scholarship Track, Jefferson Medical College of Thomas Jefferson University; Director, Division of EMS and Disaster Medicine, Albert Einstein Healthcare Network

Steven J Parrillo, DO, FACOEP, FACEP is a member of the following medical societies: American College of Emergency Physicians, American College of Osteopathic Emergency Physicians, American Osteopathic Association, World Association for Disaster and Emergency Medicine

Disclosure: Nothing to disclose.

Paul R Ogershok, MD Allergist, Allergy, Asthma, and Immunology Clinic, Southwest Regional Medical Center

Paul R Ogershok, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology, Pennsylvania Medical Society, West Virginia State Medical Association

Disclosure: Nothing to disclose.

Elena L Jones, MD Clinical Assistant Professor of Dermatology, Columbia University College of Physicians and Surgeons; Clinic Chief, Department of Dermatology, St Luke's-Roosevelt Hospital Center

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.


Jeffrey Glenn Bowman, MD, MS Consulting Staff, Highfield MRI, Columbus, Ohio

Disclosure: Nothing to disclose.

Lawrence H Brent, MD Associate Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center

Lawrence H Brent, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Physicians, and American College of Rheumatology

Disclosure: Genentech Honoraria Speaking and teaching; Genentech Grant/research funds Other; Amgen Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; Abbott Immunology Honoraria Speaking and teaching; Takeda Honoraria Speaking and teaching; UCB Speaking and teaching; Omnicare Consulting fee Consulting; Centocor Consulting fee Consulting

Herbert S Diamond, MD Professor of Medicine, Temple University School of Medicine; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, and Phi Beta Kappa

Disclosure: Merck Ownership interest Other; Smith Kline Ownership interest Other; Zimmer Ownership interest Other

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Kristine M Lohr, MD, MS Professor, Department of Internal Medicine, Center for the Advancement of Women's Health and Division of Rheumatology, Director, Rheumatology Training Program, University of Kentucky College of Medicine

Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians and American College of Rheumatology

Disclosure: Nothing to disclose.

Catherine V Parrillo, DO, FACOP, FAAP, Retired, Clinical Assistant Professor, Department of Pediatrics, Philadelphia College of Osteopathic Medicine

Catherine V Parrillo, DO, FACOP, FAAP, is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

Martin Weisse, MD Program Director, Associate Professor, Department of Pediatrics, West Virginia University

Martin Weisse, MD is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Grace M Young, MD Associate Professor, Department of Pediatrics, University of Maryland Medical Center

Grace M Young, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Emergency Physicians

Disclosure: Nothing to disclose.

  1. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi. 1967 Mar. 16(3):178-222. [Medline].

  2. Wolff AE, Hansen KE, Zakowski L. Acute Kawasaki disease: not just for kids. J Gen Intern Med. 2007 May. 22(5):681-4. [Medline]. [Full Text].

  3. Han RK, Sinclair B, Newman A, Silverman ED, Taylor GW, Walsh P, et al. Recognition and management of Kawasaki disease. CMAJ. 2000 Mar 21. 162(6):807-12. [Medline]. [Full Text].

  4. Gedalia A. Kawasaki disease: 40 years after the original report. Curr Rheumatol Rep. 2007 Aug. 9(4):336-41. [Medline].

  5. Satou GM, Giamelli J, Gewitz MH. Kawasaki disease: diagnosis, management, and long-term implications. Cardiol Rev. 2007 Jul-Aug. 15(4):163-9. [Medline].

  6. Henderson D. Kawasaki Disease Diagnosed by Urine Proteins? Medscape Medical News. December 26, 2012. Available at Accessed: January 8, 2013.

  7. Kentsis A, Shulman A, Ahmed S, Brennan E, Monuteaux MC et al. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol Med. 2012 Dec 20. [Medline].

  8. Wood L, Tulloh R. Kawasaki disease: diagnosis, management and cardiac sequelae. Expert Rev Cardiovasc Ther. 2007 May. 5(3):553-61. [Medline].

  9. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986 Aug 7. 315(6):341-7. [Medline].

  10. Salguero JS, Durán DG, Peracaula CS, Iznardi CR, Tardío JO. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab]. An Pediatr (Barc). 2010 Nov. 73(5):268-71. [Medline].

  11. Kawamura Y, Kanai T, Takeshita S, Nonoyama S. Use of the urinary trypsin inhibitor ulinastatin for acute Kawasaki disease. Nihon Rinsho. 2014 Sep. 72(9):1650-3. [Medline].

  12. Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Am J Dis Child. 1976 Jun. 130(6):599-607. [Medline].

  13. Newburger JW, Taubert KA, Shulman ST, Rowley AH, Gewitz MH, Takahashi M, et al. Summary and abstracts of the Seventh International Kawasaki Disease Symposium: December 4-7, 2001, Hakone, Japan. Pediatr Res. 2003 Jan. 53(1):153-7. [Medline].

  14. Baker AL, Lu M, Minich LL, Atz AM, Klein GL, Korsin R, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 2009 Apr. 154(4):592-595.e2. [Medline]. [Full Text].

  15. Rizk SR, El Said G, Daniels LB, Burns JC, El Said H, Sorour KA, et al. Acute Myocardial Ischemia in Adults Secondary to Missed Kawasaki Disease in Childhood. Am J Cardiol. 2014 Nov 29. [Medline].

  16. Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009 Jul. 124(1):1-8. [Medline].

  17. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther. 2010 Feb. 8(2):197-203. [Medline]. [Full Text].

  18. Burns JC, Shimizu C, Shike H, Newburger JW, Sundel RP, Baker AL, et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun. 2005 Aug. 6(5):438-44. [Medline]. [Full Text].

  19. Lee TJ, Chun JK, Yeon SI, Shin JS, Kim DS. Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease. Scand J Rheumatol. 2007 May-Jun. 36(3):222-5. [Medline].

  20. Leung DY, Schlievert PM, Meissner HC. The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum. 1998 Sep. 41(9):1538-47. [Medline].

  21. Pietra BA, De Inocencio J, Giannini EH, Hirsch R. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol. 1994 Aug 15. 153(4):1881-8. [Medline].

  22. Wang CL, Wu YT, Liu CA, Kuo HC, Yang KD. Kawasaki disease: infection, immunity and genetics. Pediatr Infect Dis J. 2005 Nov. 24(11):998-1004. [Medline].

  23. Ogawa S. Biomarker. Nihon Rinsho. 2014 Sep. 72(9):1578-84. [Medline].

  24. Onouchi Y. Susceptibility genes for Kawasaki disease. Nihon Rinsho. 2014 Sep. 72(9):1554-60. [Medline].

  25. Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, et al. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J. 2009 Nov. 28(11):943-7. [Medline].

  26. Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin Rheumatol. 2003 Dec. 22(6):461-3. [Medline].

  27. Treadwell TA, Maddox RA, Holman RC, Belay ED, Shahriari A, Anderson MS, et al. Investigation of Kawasaki syndrome risk factors in Colorado. Pediatr Infect Dis J. 2002 Oct. 21(10):976-8. [Medline].

  28. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004 Aug 7-13. 364(9433):533-44. [Medline].

  29. Melish ME, Hicks RV. Kawasaki syndrome: clinical features. Pathophysiology, etiology and therapy. J Rheumatol Suppl. 1990 Sep. 24:2-10. [Medline].

  30. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993 Dec 4. 342(8884):1385-8. [Medline].

  31. Yanagawa H, Nakamura Y, Yashiro M, Ojima T, Tanihara S, Oki I, et al. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics. 1998 Dec. 102(6):E65. [Medline].

  32. Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics. 1995 Apr. 95(4):475-9. [Medline].

  33. Pinna GS, Kafetzis DA, Tselkas OI, Skevaki CL. Kawasaki disease: an overview. Curr Opin Infect Dis. 2008 Jun. 21(3):263-70. [Medline].

  34. Caquard M, Parlier G, Siret D. [Family observation of Kawasaki disease: 2 cases in sister and brother]. Arch Pediatr. 2006 May. 13(5):453-5. [Medline].

  35. Burns JC, Shimizu C, Gonzalez E, Kulkarni H, Patel S, Shike H, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis. 2005 Jul 15. 192(2):344-9. [Medline]. [Full Text].

  36. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch Pediatr Adolesc Med. 2004 Dec. 158(12):1166-9. [Medline].

  37. Mason WH, Takahashi M, Schneider T. Recurrence of Kawasaki disease in a large urban cohort in the United States. In: Takahashi M, Taubert K, eds. Proceedings of the Fourth International Symposium on Kawasaki Disease. Dallas, Tex: American Heart Association; 1993:21-6.:

  38. Kato S, Kimura M, Tsuji K, Kusakawa S, Asai T, Juji T, et al. HLA antigens in Kawasaki disease. Pediatrics. 1978 Feb. 61(2):252-5. [Medline].

  39. Matsuda I, Hattori S, Nagata N, Fruse A, Nambu H. HLA antigens in mucocutaneous lymph node syndrome. Am J Dis Child. 1977 Dec. 131(12):1417-8. [Medline].

  40. Onouchi Y, Tamari M, Takahashi A, Tsunoda T, Yashiro M, Nakamura Y, et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet. 2007. 52(2):179-90. [Medline].

  41. Dergun M, Kao A, Hauger SB, Newburger JW, Burns JC. Familial occurrence of Kawasaki syndrome in North America. Arch Pediatr Adolesc Med. 2005 Sep. 159(9):876-81. [Medline]. [Full Text].

  42. Burns JC, Cayan DR, Tong G, Bainto EV, Turner CL, Shike H, et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology. 2005 Mar. 16(2):220-5. [Medline]. [Full Text].

  43. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008 Jan. 40(1):35-42. [Medline]. [Full Text].

  44. Breunis WB, Biezeveld MH, Geissler J, Kuipers IM, Lam J, Ottenkamp J, et al. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin Exp Immunol. 2007 Oct. 150(1):83-90. [Medline]. [Full Text].

  45. Mamtani M, Matsubara T, Shimizu C, et al. Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children. PLoS One. Jul 7 2010;5(7):e11458:

  46. Taniuchi S, Masuda M, Teraguchi M, Ikemoto Y, Komiyama Y, Takahashi H, et al. Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. J Clin Immunol. 2005 Jul. 25(4):309-13. [Medline].

  47. Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010 Jun. 29(6):483-8. [Medline].

  48. Falcini F, Ozen S, Magni-Manzoni S, Candelli M, Ricci L, Martini G, et al. Discrimination between incomplete and atypical Kawasaki syndrome versus other febrile diseases in childhood: results from an international registry-based study. Clin Exp Rheumatol. 2012 Sep-Oct. 30:799-804. [Medline].

  49. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005 May. 146(5):662-7. [Medline].

  50. Yanagawa H, Nakamura Y, Yashiro M, Uehara R, Oki I, Kayaba K. Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999-2002. Pediatr Int. 2006 Aug. 48(4):356-61. [Medline].

  51. Park YW, Han JW, Park IS, Kim CH, Cha SH, Ma JS, et al. Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J. 2007 Sep. 26(9):821-3. [Medline].

  52. Huang GY, Ma XJ, Huang M, Chen SB, Huang MR, Gui YH, et al. Epidemiologic pictures of Kawasaki disease in Shanghai from 1998 through 2002. J Epidemiol. 2006 Jan. 16(1):9-14. [Medline].

  53. Royle JA, Williams K, Elliott E, Sholler G, Nolan T, Allen R, et al. Kawasaki disease in Australia, 1993-95. Arch Dis Child. 1998 Jan. 78(1):33-9. [Medline]. [Full Text].

  54. Harnden A, Alves B, Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ. 2002 Jun 15. 324(7351):1424-5. [Medline]. [Full Text].

  55. Lin YT, Manlhiot C, Ching JC, Han RK, Nield LE, Dillenburg R, et al. Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int. 2010 Oct. 52(5):699-706. [Medline].

  56. Nakamura Y. Epidemiology of Kawasaki disease. Nihon Rinsho. 2014 Sep. 72(9):1536-41. [Medline].

  57. Stankovic K, Miailhes P, Bessis D, Ferry T, Broussolle C, Sève P. Kawasaki-like syndromes in HIV-infected adults. J Infect. 2007 Dec. 55(6):488-94. [Medline].

  58. Pannaraj PS, Turner CL, Bastian JF, Burns JC. Failure to diagnose Kawasaki disease at the extremes of the pediatric age range. Pediatr Infect Dis J. 2004 Aug. 23(8):789-91. [Medline].

  59. Manlhiot C, Yeung RS, Clarizia NA, Chahal N, McCrindle BW. Kawasaki disease at the extremes of the age spectrum. Pediatrics. 2009 Sep. 124(3):e410-5. [Medline].

  60. Kim T, Choi W, Woo CW, Choi B, Lee J, Lee K, et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr. 2007 May. 166(5):421-5. [Medline].

  61. Choi JY, Park SY, Choi KH, Park YH, Lee YH. Clinical characteristics of Kawasaki disease with sterile pyuria. Korean J Pediatr. 2013 Jan. 56(1):13-8. [Medline]. [Full Text].

  62. Gupta-Malhotra M, Gruber D, Abraham SS, Roman MJ, Zabriskie JB, Hudgins LC, et al. Atherosclerosis in survivors of Kawasaki disease. J Pediatr. 2009 Oct. 155(4):572-7. [Medline].

  63. Kitamura S, Tsuda E, Kobayashi J, Nakajima H, Yoshikawa Y, Yagihara T, et al. Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. Circulation. 2009 Jul 7. 120(1):60-8. [Medline].

  64. Yeo Y, Kim T, Ha K, Jang G, Lee J, Lee K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr. 2009 Feb. 168(2):157-62. [Medline].

  65. Wilder MS, Palinkas LA, Kao AS, Bastian JF, Turner CL, Burns JC. Delayed diagnosis by physicians contributes to the development of coronary artery aneurysms in children with Kawasaki syndrome. Pediatr Infect Dis J. 2007 Mar. 26(3):256-60. [Medline]. [Full Text].

  66. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004 Oct 26. 110(17):2747-71. [Medline].

  67. Nomura Y, Arata M, Koriyama C, Masuda K, Morita Y, Hazeki D, et al. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission. J Pediatr. 2010 May. 156(5):786-91. [Medline].

  68. Ulloa-Gutierrez R, Acón-Rojas F, Camacho-Badilla K, Soriano-Fallas A. Pustular rash in Kawasaki syndrome. Pediatr Infect Dis J. 2007 Dec. 26(12):1163-5. [Medline].

  69. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics. 2015 Aug 24. [Medline].

  70. Boggs W. Concurrent Respiratory Viruses Common in Children With Kawasaki Disease. Available at August 31, 2015; Accessed: September 14, 2015.

  71. Belay ED, Maddox RA, Holman RC, Curns AT, Ballah K, Schonberger LB. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. Pediatr Infect Dis J. 2006 Mar. 25(3):245-9. [Medline].

  72. Goo HW, Park IS, Ko JK, Kim YH. Coronary CT angiography and MR angiography of Kawasaki disease. Pediatr Radiol. 2006 Jul. 36(7):697-705. [Medline].

  73. Mavrogeni S, Papadopoulos G, Douskou M, Kaklis S, Seimenis I, Baras P, et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol. 2004 Feb 18. 43(4):649-52. [Medline].

  74. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr. 2004 Oct. 16(5):508-14. [Medline].

  75. Manlhiot C, Christie E, McCrindle BW, Rosenberg H, Chahal N, Yeung RS. Complete and incomplete Kawasaki disease: two sides of the same coin. Eur J Pediatr. 2011 Dec 3. [Medline].

  76. Heuclin T, Dubos F, Hue V, Godart F, Francart C, Vincent P, et al. Increased detection rate of Kawasaki disease using new diagnostic algorithm, including early use of echocardiography. J Pediatr. 2009 Nov. 155(5):695-9.e1. [Medline].

  77. Hinze CH, Graham TB, Sutherell JS. Kawasaki disease without fever. Pediatr Infect Dis J. 2009 Oct. 28(10):927-8. [Medline].

  78. Printz BF, Sleeper LA, Newburger JW, Minich LL, Bradley T, Cohen MS, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol. 2011 Jan 4. 57(1):86-92. [Medline].

  79. Kanamaru H, Sato Y, Takayama T, Ayusawa M, Karasawa K, Sumitomo N, et al. Assessment of coronary artery abnormalities by multislice spiral computed tomography in adolescents and young adults with Kawasaki disease. Am J Cardiol. 2005 Feb 15. 95(4):522-5. [Medline].

  80. Dadlani GH, Gingell RL, Orie JD, Roland JM, Najdzionek J, Lipsitz SR, et al. Coronary artery calcifications in the long-term follow-up of Kawasaki disease. Am Heart J. 2005 Nov. 150(5):1016. [Medline].

  81. Weedon R. Kawasaki Syndrome: The vasculopathic reaction pattern In:. Pathology. 2002:238-9:

  82. Chen X, Zhao ZW, Li L, Chen XJ, Xu H, Lou JT, et al. Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease. Lipids Health Dis. 2015 Dec 30. 14(1):166. [Medline].

  83. Watanabe K, Suzuki H, Jiang M, Haniu H, Numano F, Hoshina S, et al. Soluble LR11 is a novel biomarker for vascular lesions late after Kawasaki disease. Atherosclerosis. 2015 Dec 29. 246:94-97. [Medline].

  84. Uehara R, Yashiro M, Oki I, Nakamura Y, Yanagawa H. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey. Pediatr Int. 2007 Aug. 49(4):427-30. [Medline].

  85. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008 Jul. 153(1):117-21. [Medline]. [Full Text].

  86. Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. Singapore Med J. 2006 Sep. 47(9):780-4. [Medline].

  87. Zulian F, Zanon G, Martini G, Mescoli G, Milanesi O. Efficacy of infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol. 2006 Jul-Aug. 24(4):453. [Medline].

  88. Stenbøg EV, Windelborg B, Hørlyck A, Herlin T. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006 Jul-Aug. 35(4):318-21. [Medline].

  89. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008 Dec. 153(6):833-8. [Medline]. [Full Text].

  90. Youn Y, Kim J, Hong YM, Sohn S. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin. Pediatr Infect Dis J. 2015 Dec 15. [Medline].

  91. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics. 2004 Dec. 114(6):e689-93. [Medline].

  92. Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2006 Oct 18. CD004175. [Medline].

  93. Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006 Sep. 149(3):336-341. [Medline].

  94. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007 Feb 15. 356(7):663-75. [Medline].

  95. Athappan G, Gale S, Ponniah T. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature. Cardiovasc J Afr. 2009 Jul-Aug. 20(4):233-6. [Medline].

  96. Phillips B. Review: corticosteroids with intravenous immunoglobulin reduced the incidence of coronary artery aneurysm formation in patients with Kawasaki disease. Arch Dis Child Educ Pract Ed. 2013 Feb 7. [Medline].

  97. Douglas D. IVIG Plus Prednisolone Promising in Refractory Kawasaki Disease. Medscape. Mar 18 2013. [Full Text].

  98. Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. Aug 2013. 163(2):521-526.e1. [Medline].

Patchy generalized macular erythema, which is also typical of some viral exanthems.
Peeling and erythema of the fingertips.
Strawberry tongue.
Pediatrics, Kawasaki disease. Note the appearance of the hand and lips. Photo courtesy of Sam Richardson, MD.
Clinical manifestations and time course of Kawasaki disease.
Oral manifestations of Kawasaki disease: red lips and strawberry tongue.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.